# reload+after+2024-01-22 04:45:24.311370
address1§3350 Riverwood Parkway SE
address2§Suite 1900
city§Atlanta
state§GA
zip§30339
country§United States
phone§678 392 3419
website§https://www.inhibikase.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
fullTimeEmployees§6
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Milton H. Werner Ph.D.', 'age': 59, 'title': 'CEO, President & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 658190, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph  Frattaroli CPA', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 531833, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roger  Rush', 'title': 'Head of Preclinical Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Surendra  Singh', 'title': 'Head of Chemistry, Manufacturing & Controls', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.', 'title': 'CEO of Clintrex Research Corporation & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dan  Williams', 'title': 'Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.216
priceToSalesTrailing12Months§25.530401
currency§USD
dateShortInterest§1702598400
forwardEps§-4.33
exchange§NCM
quoteType§EQUITY
shortName§Inhibikase Therapeutics, Inc.
longName§Inhibikase Therapeutics, Inc.
firstTradeDateEpochUtc§1608733800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§df2742fe-620d-3418-ba9f-016d7a873d41
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§27.0
targetMeanPrice§27.0
targetMedianPrice§27.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§6.139
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
